Delivery Order SPE2DB22D1056-SPE2DB25FSHP4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $44,261.94 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 2 GM vials. This contract, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, operates under a firm fixed-price arrangement with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $2,580.30 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 1 GM vials, with an ultimate completion date of September 5, 2025. This is a firm fixed-price, non-set-aside contract with performance at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The Defense Logistics Agency awarded a $1,867.90 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Cyclophosphamide 500 mg vials, with an ultimate completion date of September 17, 2025. This firm fixed-price contract represents a non-set-aside award issued through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials under a firm fixed-price contract valued at $1,226.03. This competitively awarded, non-set-aside delivery order was issued on June 30, 2025, with an ultimate completion date of July 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Cyclophosphamide is a critical chemotherapy agent used in military and federal healthcare...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $26,197.80 on July 22, 2025, for the supply of Cyclophosphamide 2 GM vials, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,316.80 to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Cyclophosphamide 1 GM/5 ML vials (5 ML quantity). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 18, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Cyclophosphamide 1 GM/5 ML VL 5 ML, a pharmaceutical product, with a potential value of $2,080.34 and a completion date of March 1, 2024. Amerisourcebergen Drug Corp is the prime contractor for this delivery order, which is not part of a set-aside program. In addition to this specific...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office Division. The $3,735.80 contract is for the delivery of Cyclophosphamide 500 mg vials, a critical pharmaceutical product. The award has an ultimate completion date of August 19, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which enables the government to...
- AmerisourceBergen Drug Corp received a delivery order award from the Defense Logistics Agency Medical Supply Chain on July 15, 2025, for the supply of Cyclophosphamide 2 GM/10 ML vials (10 mL quantity) with a ceiling value of $2,032.66. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively on an open basis. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. The...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,118,918 units of the pharmaceutical product Cyclophosphamide 1 GM/5 ML VL 5ML. The order, valued at $1,449.08, has an ultimate completion date of April 1, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA Troop Support Medical, valued...
- SPE2DB22D1056Indefinite Delivery Contract
- SPE2DB22D1056-SPE2DB25FSHP4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,120.74 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials. The contract, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, operates under firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order supports the Defense Health Agency and broader military healthcare operations through AmerisourceBergen's pharmaceutical distribution capabilities. Cyclophosphamide is a critical chemotherapy and immunosuppressive agent used in military and veteran medical treatment. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen was competitively selected to fulfill this requirement, demonstrating its established position as a primary vendor for federal medical procurement. The firm fixed price contract structure ensures predictable costs for this essential pharmaceutical commodity supporting defense health requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/8/25 |